About the Company
paratek pharmaceuticals (nasdaq: prtk) is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. we focus on drugs that target infectious disease and other difficult to treat conditions. our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against gram-positive, gram-negative and atypical bacteria. omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. the food and drug administration (fda) granted omadacycline a qualified infectious disease product (qidp) designation and completed two special protocol assessments for its phase 3 clinical trial program.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PRTK News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Is Expected To Breakeven In The Near Future
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Paratek Pharmaceuticals, Inc., a ...
Paratek Reports Positive Data For Nuzyra As Post-exposure Prophylaxis Of Pulmonary Anthrax In NHPs
(RTTNews) - Paratek Pharmaceuticals, Inc. (PRTK) Tuesday announced positive topline efficacy data for Nuzyra as post-exposure prophylaxis (PEP) of pulmonary anthrax in non-human primates (NHPs).
What is the Pipeline for Gram-negative Pathogens?
and Timothy Babinchak (Wyeth Pharmaceuticals); Ann Macone and Robert Arbeit (Paratek Pharmaceuticals, Inc.); Karen Bush and Robert Flamm (Johnson & Johnson); Brian Dannemann (Hoffmann La Roche ...
Nuvectis Pharma, Inc. (NVCT)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...
Ionis Pharmaceuticals Inc IONS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Vertex Pharmaceuticals Inc VRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Amneal Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
AVIR Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product ...
KPRX Kiora Pharmaceuticals, Inc.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead ...
Loading the latest forecasts...